CPRX vs. ANIP, IDYA, PGNX, SYRS, DRRX, RVMD, ELAN, SMMT, KRYS, and OGN
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include ANI Pharmaceuticals (ANIP), IDEAYA Biosciences (IDYA), Progenics Pharmaceuticals (PGNX), Syros Pharmaceuticals (SYRS), DURECT (DRRX), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "medical" sector.
ANI Pharmaceuticals (NASDAQ:ANIP) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.
ANI Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of 6.87%. ANI Pharmaceuticals' return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals has lower revenue, but higher earnings than ANI Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalyst Pharmaceuticals received 59 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 74.43% of users gave Catalyst Pharmaceuticals an outperform vote while only 64.70% of users gave ANI Pharmaceuticals an outperform vote.
ANI Pharmaceuticals presently has a consensus target price of $82.75, suggesting a potential upside of 32.91%. Catalyst Pharmaceuticals has a consensus target price of $27.80, suggesting a potential upside of 58.04%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than ANI Pharmaceuticals.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Catalyst Pharmaceuticals had 6 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 8 mentions for Catalyst Pharmaceuticals and 2 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.63 beat Catalyst Pharmaceuticals' score of 0.56 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Summary
Catalyst Pharmaceuticals beats ANI Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
Free CPRX Stock Alerts